-
Something wrong with this record ?
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
D. Schierova, R. Roubalova, M. Kolar, Z. Stehlikova, F. Rob, Z. Jackova, S. Coufal, T. Thon, M. Mihula, M. Modrak, M. Kverka, L. Bajer, K. Kostovcikova, P. Drastich, J. Hercogova, M. Novakova, M. Vasatko, M. Lukas, H. Tlaskalova-Hogenova, Z....
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
grant number NV18-09-00493.
Ministry of Health of the Czech Republic
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2012-03-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
34831411
DOI
10.3390/cells10113188
Knihovny.cz E-resources
- MeSH
- Biodiversity MeSH
- Adult MeSH
- Feces microbiology MeSH
- Fungi genetics MeSH
- Inflammatory Bowel Diseases blood drug therapy microbiology surgery MeSH
- Tumor Necrosis Factor Inhibitors therapeutic use MeSH
- Interleukin-17 metabolism MeSH
- Leukocytes, Mononuclear metabolism MeSH
- Humans MeSH
- Metagenomics MeSH
- Antibodies blood MeSH
- RNA, Ribosomal, 16S genetics MeSH
- Gastrointestinal Microbiome * genetics MeSH
- Case-Control Studies MeSH
- Severity of Illness Index MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn's disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).
IBD Clinical and Research Centre ISCARE a s 190 00 Prague Czech Republic
Institute of Microbiology of the Czech Academy of Sciences 142 20 Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003196
- 003
- CZ-PrNML
- 005
- 20240206093047.0
- 007
- ta
- 008
- 220113s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cells10113188 $2 doi
- 035 __
- $a (PubMed)34831411
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Schierova, Dagmar $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 245 10
- $a Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy / $c D. Schierova, R. Roubalova, M. Kolar, Z. Stehlikova, F. Rob, Z. Jackova, S. Coufal, T. Thon, M. Mihula, M. Modrak, M. Kverka, L. Bajer, K. Kostovcikova, P. Drastich, J. Hercogova, M. Novakova, M. Vasatko, M. Lukas, H. Tlaskalova-Hogenova, Z. Jiraskova Zakostelska
- 520 9_
- $a Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn's disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protilátky $x krev $7 D000906
- 650 _2
- $a biodiverzita $7 D044822
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a feces $x mikrobiologie $7 D005243
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a houby $x genetika $7 D005658
- 650 12
- $a střevní mikroflóra $x genetika $7 D000069196
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiopatické střevní záněty $x krev $x farmakoterapie $x mikrobiologie $x chirurgie $7 D015212
- 650 _2
- $a interleukin-17 $x metabolismus $7 D020381
- 650 _2
- $a leukocyty mononukleární $x metabolismus $7 D007963
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metagenomika $7 D056186
- 650 _2
- $a RNA ribozomální 16S $x genetika $7 D012336
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Roubalova, Radka $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Kolar, Martin $u IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic
- 700 1_
- $a Stehlikova, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Rob, Filip $u Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic
- 700 1_
- $a Jackova, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Coufal, Stepan $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Thon, Tomas $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Mihula, Martin $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Modrák, Martin $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic $7 xx0313530
- 700 1_
- $a Kverka, Miloslav $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Bajer, Lukas $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic $u Institute for Clinical and Experimental Medicine of the Czech Academy of Science, 140 21 Prague, Czech Republic
- 700 1_
- $a Kostovcikova, Klara $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Drastich, Pavel $u Institute for Clinical and Experimental Medicine of the Czech Academy of Science, 140 21 Prague, Czech Republic
- 700 1_
- $a Hercogova, Jana $u Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic
- 700 1_
- $a Novakova, Michaela $u Dermatovenerology Department, Second Faculty of Medicine, University Hospital Bulovka, Charles University in Prague, 180 81 Prague, Czech Republic
- 700 1_
- $a Vasatko, Martin $u IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic
- 700 1_
- $a Lukas, Milan $u IBD Clinical and Research Centre ISCARE a.s., 190 00 Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic
- 700 1_
- $a Tlaskalova-Hogenova, Helena $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Jiraskova Zakostelska, Zuzana $u Institute of Microbiology of the Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 773 0_
- $w MED00194911 $t Cells $x 2073-4409 $g Roč. 10, č. 11 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34831411 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20240206093044 $b ABA008
- 999 __
- $a ok $b bmc $g 1750839 $s 1154345
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 10 $c 11 $e 20211116 $i 2073-4409 $m Cells $n Cells $x MED00194911
- GRA __
- $a grant number NV18-09-00493. $p Ministry of Health of the Czech Republic
- LZP __
- $a Pubmed-20220113
